Evolus, a performance beauty company, extended the expiration date of the second undrawn tranche under its existing term loan financing facility with investment funds managed by Pharmakon Advisors to Dec. 31, 2023.
Coherus BioSciences entered into a loan agreement with investment funds managed by Pharmakon Advisors. The agreement provides an up to $300 million credit facility, with funds spread across four tranches.
TESARO, an oncology-focused biopharmaceutical company, entered into a definitive term loan agreement with Biopharma Credit and BioPharma Credit Investments IV, investment funds managed by Pharmakon Advisors.
Halozyme Therapeutics closed a $150 million royalty-backed debt transacton with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.
Halozyme Therapeutics entered into a $150 million royalty-back debt financing with BioPharma Credit Investments as collateral agent and lender and Athryrium Capital Management as lender.